These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 38662902)
1. An update on migraine: Current and new treatment options. Hervias T JAAPA; 2024 May; 37(5):1-7. PubMed ID: 38662902 [TBL] [Abstract][Full Text] [Related]
2. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Ailani J; Burch RC; Robbins MS; Headache; 2021 Jul; 61(7):1021-1039. PubMed ID: 34160823 [TBL] [Abstract][Full Text] [Related]
3. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. VanderPluym JH; Halker Singh RB; Urtecho M; Morrow AS; Nayfeh T; Torres Roldan VD; Farah MH; Hasan B; Saadi S; Shah S; Abd-Rabu R; Daraz L; Prokop LJ; Murad MH; Wang Z JAMA; 2021 Jun; 325(23):2357-2369. PubMed ID: 34128998 [TBL] [Abstract][Full Text] [Related]
9. Update on noninvasive neuromodulation for migraine treatment-Vagus nerve stimulation. Schoenen J; Ambrosini A Prog Brain Res; 2020; 255():249-274. PubMed ID: 33008508 [TBL] [Abstract][Full Text] [Related]
10. Prevention of Migraine. Holdridge A; Buczyner J; Aymat CC; Le A Semin Neurol; 2022 Oct; 42(5):558-570. PubMed ID: 36513096 [TBL] [Abstract][Full Text] [Related]
11. A device review of Relivion®: an external combined occipital and trigeminal neurostimulation (eCOT-NS) system for self-administered treatment of migraine and major depressive disorder. Daniel O; Sharon R; Tepper SJ Expert Rev Med Devices; 2021 Apr; 18(4):333-342. PubMed ID: 33787443 [No Abstract] [Full Text] [Related]
12. External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial. Daniel O; Tepper SJ; Deutsch L; Sharon R Pain Ther; 2022 Sep; 11(3):907-922. PubMed ID: 35661128 [TBL] [Abstract][Full Text] [Related]
13. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study. Kinfe TM; Pintea B; Muhammad S; Zaremba S; Roeske S; Simon BJ; Vatter H J Headache Pain; 2015; 16():101. PubMed ID: 26631234 [TBL] [Abstract][Full Text] [Related]
16. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. van Hoogstraten WS; MaassenVanDenBrink A J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904 [TBL] [Abstract][Full Text] [Related]
17. Future prophylactic treatments in migraine: Beyond anti-CGRP monoclonal antibodies and gepants. Do TP; Al-Saoudi A; Ashina M Rev Neurol (Paris); 2021 Sep; 177(7):827-833. PubMed ID: 34294458 [TBL] [Abstract][Full Text] [Related]
18. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A; Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028 [TBL] [Abstract][Full Text] [Related]